Breast cancer patients who carry the wild-type gene required for tamoxifen metabolism may have comparable risk of recurrence when taking tamoxifen or an aromatase inhibitor, according to modeling data ...
... caused by L. amazonensis.
The promising results presented in this study, coupled with the fact that tamoxifen's safety and pharmacological profiles in humans are well established, point to a new ...
... diagnosed with breast cancer each year, roughly 70% of which will have cancers treatable with tamoxifen. Unfortunately, 30% or more of these women may not respond well to such anti-hormone therapy ...
... a new player and shows some of its downstream signaling and how this affects responsiveness to tamoxifen in these breast cancers."
The findings came about after the research team developed the first ...
... to the direct effects of oestrogen withdrawal. Dr. Hiscox said, "Anti-oestrogens, such as tamoxifen, have been the mainstay of therapy in patients with oestrogen receptor positive (ER+) breast cancer ...
... that women with an inherited deficiency in the CYP2D6 gene, which is important for the metabolism of tamoxifen, have a nearly fourfold higher risk of early breast cancer recurrence compared to women ...
... research suggests that in patients who show reduced or absent expression of the protein E-cadherin, commonly used anti-estrogen drugs such as tamoxifen may promote more harmful cancer cell behavior.
... a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer and that it works against cancer in an entirely unexpected ...
... the mitochondria."
This study continues a string of discoveries the researchers have made regarding tamoxifen resistance. They had earlier found that invasive lobular breast cancer has many more so- ...
... abundance levels in the two tumor groups, highlighting a potential profile for tamoxifen resistance.
In addition, they analyzed the most significantly altered protein, called extracellular matrix ...
... that activation of GF signaling contributes to this highly proliferative, relatively tamoxifen-insensitive, phenotype and that this exists independently of HER2 overexpression. Targeting this pathway ...
... the Department of Chemical Biology at the Oregon Health Sciences University in Portland.
"Tamoxifen and other synthetic estrogens have been known to increase the risk of uterine cancer, but until now ...
... the lives of half a million women have been saved with adjuvant [supplemental] tamoxifen therapy," according to background information in the article. The growth inhibitory effect of tamoxifen is ...
Among women with early stage breast cancer, genetic variation of a certain enzyme appears to be associated with clinical outcomes for women treated with tamoxifen, according to a new study.
... . Their presence can determine whether tumors will respond to the estrogen-blocking drug tamoxifen.
The finding will help researchers sort out how mutations change the estrogen receptor's function ...
